BRAF and melanoma: To further evaluate the impact of this novel predictive biomarker identified by KL-Relevance approach, we then assessed drug responses in four melanoma cell lines under varying EZH2 and BRAF statuses treated with PLX-4720 (Fig. 4a, b).